Niclosamide is reported to disrupt PD-1/PD-L1 interactions in non-small cell lung cancer (153), metastatic lung adenocarcinoma (154), and pancreatic cancer (41, 155) primarily through PD-L1 ligand downregulation in cancer cells. This evidence concerns the gene CD274 and familial pancreatic carcinoma.